Nexus Biopharma Inc. | Income Statement
Fiscal year is March-February. All values USD Thousands.
2012
2013
2014
2016
2017
Cost of Goods Sold (COGS) incl. D&A
-
-
-
-
1.50
Gross Income
-
-
-
-
1.50
SG&A Expense
23.40
15.30
1.40
-
653.60
EBIT
23.40
15.30
1.40
-
655.10
Unusual Expense
7.00
-
-
-
-
Non Operating Income/Expense
7.00
-
-
-
-
Interest Expense
-
-
-
-
31.00
Pretax Income
9.40
15.30
1.40
-
686.10
Consolidated Net Income
9.40
15.30
1.40
-
686.10
Net Income
9.40
15.30
1.40
-
686.10
Net Income After Extraordinaries
9.40
15.30
1.40
-
686.10
Net Income Available to Common
9.40
15.30
1.40
-
686.10
EPS (Basic)
-
0.00
-
-
0.01
Basic Shares Outstanding
191,400.00
63,800.00
63,800.00
-
55,789.60
EPS (Diluted)
0.00
0.00
0.00
-
0.01
Diluted Shares Outstanding
191,400.00
63,800.00
63,800.00
-
55,789.60
EBITDA
23.40
15.30
1.40
-
653.60
Non-Operating Interest Income
-
-
-
-
0.00
About Nexus Biopharma
View Profile
